Home › Funds › Seven Fleet Capital Management LP › SABS
Seven Fleet Capital Management LP position in SABS
SAB BIOTHERAPEUTICS INC · Health Care
Seven Fleet Capital Management LP reported holding 736,077 shares of SABS (SAB BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$2.9M, representing 0.47% of its reported portfolio and ranking #36 among its reported holdings. Seven Fleet Capital Management LP has disclosed SABS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Seven Fleet Capital Management LP's SABS position evolved
Seven Fleet Capital Management LP first disclosed a stake in SABS in Q1 2026 at 100,000 shares (US$383K). The position peaked in Q2 2026 at 736,077 shares, worth US$2.9M. Across 2 filings, Seven Fleet Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 736,077 shares valued at US$2.9M — an increase of 636,077 shares quarter over quarter.. Notable position changes include a 636% increase in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 100.00K | $383.00K | New |
| Q2 2026 | 736.08K | $2.87M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SABS and 13F data
SABS (SAB BIOTHERAPEUTICS INC) is a Health Care company. 77 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Vivo Capital, LLC (US$28.5M), Commodore Capital LP (US$11.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SABS
- Caligan Partners LP 7.97M sh · $31.07M · Q2 2026
- Vivo Capital, LLC 7.30M sh · $28.47M · Q2 2026
- Commodore Capital LP 2.87M sh · $11.19M · Q2 2026
- Spruce Street Capital LP 2.20M sh · $8.57M · Q2 2026
- Sessa Capital IM, L.P. 2.20M sh · $8.57M · Q2 2026
- Propel Bio Management, LLC 1.08M sh · $4.20M · Q2 2026
More on Seven Fleet Capital Management LP
FAQ
How long has Seven Fleet Capital Management LP held SABS?
Seven Fleet Capital Management LP has disclosed SABS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Seven Fleet Capital Management LP's current position in SABS?
As of Q2 2026, Seven Fleet Capital Management LP holds 736.08K shares of SABS (SAB BIOTHERAPEUTICS INC), valued at $2.87M, representing 0.47% of its reported portfolio and ranking #36.
Has Seven Fleet Capital Management LP been buying or selling SABS?
In the latest 13F filing (Q2 2026), Seven Fleet Capital Management LP increased its position in SABS. The position peaked in Q2 2026 at 736.08K shares.
Which other funds hold SABS?
Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, Commodore Capital LP, among 77 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.